Big Molecule Watch
September 19, 2018

California Sues AbbVie Over Alleged Kickbacks for HUMIRA

In a complaint filed yesterday, the State of California sued AbbVie, Inc. based on an alleged kickback scheme in connection with AbbVie’s Humira® (adalimumab).  The complaint alleges that AbbVie violated the Insurance Frauds Prevention Act (“IFPA”) by providing kickbacks to health providers throughout California.  Specifically, AbbVie allegedly indirectly paid healthcare providers to prescribe Humira® by offering “classic” kickbacks such as cash, meals, drinks, gifts, trips, and patient referrals, and by sending registered nurses to provide home care services for patients who were prescribed Humira®.  This conduct, the complaint alleges, led healthcare providers to write far greater numbers of Humira® prescriptions than they would have otherwise written.  California seeks as damages three times the amount of each claim for compensation pursuant to contracts of insurance made for Humira®, civil penalties of $10,000 for each fraudulent claim presented to an insurance company, injunctive relief, and attorneys’ fees and costs.

The post California Sues AbbVie Over Alleged Kickbacks for HUMIRA appeared first on Big Molecule Watch.